Early tox material can offer valuable clarity as programs progress toward IND. Lonza’s latest white paper introduces a new offering that helps drug developers shorten timelines and generate tox material in as little as 2.5 months. Inside, you will find insights on: Strategies from this new approach that… Read More
Discover how ProBio accelerates bispecific antibody development with optimised cell line strategies. This guide highlights proven methods such as two-vector expression systems and NGS‑enabled clone selection to improve purity, productivity, and manufacturing robustness. You will learn: How to reduce bispecific antibody impurities through chain‑ratio optimisation Methods to enhance… Read More
Key highlights: Comprehensive explanation of the newly revised USP General Chapters 41 and 1251 Practical advice on how to implement these revised requirements effectively Guidance to help ensure compliance with updated USP weighing standards Download now. Read More
Key highlights: Comprehensive explanation of the newly revised USP General Chapters 41 and 1251 Practical advice on how to implement these revised requirements effectively Guidance to help ensure compliance with updated USP weighing standards Brought to you by Copyright 2026 Drug… Read More
The kinetic profile of degrader compounds is critical to optimised design, showing how live-cell kinetic analysis transforms discovery. This Whitepaper reveals how tracking protein dynamics in live cells delivers richer, more actionable data to improve compound optimisation across programmes. The Whitepaper will discuss: Why kinetic data deliver deeper context than… Read More
The kinetic profile of degrader compounds is critical to optimised design, showing how live-cell kinetic analysis transforms discovery. This whitepaper reveals how tracking protein dynamics in live cells delivers richer, more actionable data to improve compound optimisation across programs. We’ll discuss: Why kinetic data deliver deeper context than single-time-point… Read More
Neurological biomarker research is advancing rapidly, but key challenges remain. This whitepaper captures: Expert perspectives from academia and biopharma Highlighting successes, setbacks, and strategies for translational advancements in Alzheimer’s, Parkinson’s, and MS. A must-read for researchers navigating the future of precision neurology. Brought to… Read More
Neurological biomarker research is advancing rapidly, but key challenges remain. This Whitepaper captures: Expert perspectives from academia and biopharma Highlighting successes, setbacks, and strategies for translational advancements in Alzheimer’s, Parkinson’s, and MS. A must-read for researchers navigating the future of precision neurology. Read More
Neurological biomarker research is advancing rapidly, but key challenges remain. This whitepaper captures: Expert perspectives from academia and biopharma Highlighting successes, setbacks, and strategies for translational advancements in Alzheimer’s, Parkinson’s, and MS. A must-read for researchers navigating the future of precision neurology. Brought to… Read More
Today’s drug discovery teams face increasing pressure to accelerate timelines, improve translational success, and minimise costly clinical failures. Yet most platforms still rely on fragmented technologies that deliver partial or delayed insights—forcing you to reconstruct biology from disconnected data. AVITI24™ 5D multiomics platform offers a new path by capturing RNA,… Read More
The tumour microenvironment (TME) is no longer considered a passive backdrop to cancer. It is a dynamic ecosystem that plays a central role in tumour growth, immune suppression, metastasis and treatment resistance. Whitepaper highlights: Understand how the TME drives cancer progression, immune evasion and therapeutic resistance Explore emerging strategies that… Read More